# Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

> **NCT00403260** · PHASE3 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 1271 (actual)

## Conditions studied

- Falciparum Malaria

## Interventions

- **DRUG:** Pyronaridine - artesunate
- **DRUG:** Mefloquine plus artesunate

## Key facts

- **NCT ID:** NCT00403260
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 1271 (ACTUAL)
- **Last updated:** 2021-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403260, "Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00403260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*